Abstract:Background: Glioblastoma (GBM) is the most common and lethal primary brain tumor with low effectiveness of available treatments. The tumor heterogeneity and therapeutic resistance are largely due to the presence of glioma stem cells (GSCs). Therefore, eliminating GSCs can overcome the progression, relapse, and resistance of GBM. Previous studies have shown that gambogic acid (GA), a natural active ingredient, has anti-glioma properties. Nonetheless, it is still unclear whether it has an inhibitory effect on GSCs and what its target might be. This study aimed to investigate the anti-tumor effects of GA on GSCs. In addition, this study found the target of GA in GSCs and elucidated the potential specific mechanisms by conducting both in vitro and in vivo experiments. B-cell-specific Moloney leukemia virus insert site 1 (BMI1) is a key stem cell factor of the polycomb group (PcG) family with important effects on the development, recurrence, and chemoresistance of several cancers. In both normal and cancer stem cells, BMI1 maintains stem cell self-renewal by regulating the cell cycle, cellular immortalization, and senescence. Its high expression in a variety of cancers correlates with poor clinical prognosis and chemoresistance. These mechanisms of BMI1 make it a potential therapeutic target for cancer therapy, and future studies may further reveal the specific roles of BMI1 mechanism and provide a basis for the development of new cancer therapeutic strategies. Purpose: This study investigated the in vitro and in vivo effects of GA in inducing apoptosis in GSCs and inhibiting GSCs self-renewal, as well as its underlying mechanisms. Methods: This study synthesized biotinylated gambogic acid for the first time and angled for the target of gambogic acid using LC-MS/MS analysis, which has not been reported previously. Human-derived glioma stem cells GSC123 and GSC111 were used for in vitro studies, analyzing functions and mechanisms via microscale thermophoresis (MST), Annexin V/PI staining, Western blotting, immunofluorescence, and co-immunoprecipitation. The orthotopic glioma mouse model was used to assess the anti-tumor effects of GA in vivo. Results: This study demonstrated that GA is a specific inhibitor of BMI1, a key regulator controlling stem cell growth and self-renewal. GA binds to BMI1's RING domain, accelerating K51-dependent degradation and suppressing H2A ubiquitination. Importantly, GA induces apoptosis, and inhibits GSC self-renewal, but minimally impacts neural progenitor cells (NPCs). GA can also be combined effectively with temozolomide and radiotherapy to increase their sensitivities in resistant cells. Furthermore, exogenous induction of BMI1 expression significantly hinders the disruption of GSCs by GA. In vivo, GA inhibits tumorigenicity, enhances the effect of temozolomide, and reduces BMI1 expression. Conclusion: These findings suggest that GA is a potential candidate for targeting GSCs and therefore be used to treat GBM.

Growth Inhibitory in Vitro Effects of Glycyrrhizic Acid in U251 Glioblastoma Cell Line

Inhibitory effects of Glycyrrhizic acid on human glioma U251 cells and nuclear factor κB

Ginkgolic Acid Inhibits Proliferation and Migration of Glioblastoma Cells by Inducing Cell Cycle Arrest and Apoptosis

Autophagy Inhibition Promotes Gambogic Acid-Induced Suppression Of Growth And Apoptosis In Glioblastoma Cells

CCL2-targeted ginkgolic acid exerts anti-glioblastoma effects by inhibiting the JAK3-STAT1/PI3K-AKT signaling pathway

Gambogenic acid-induced time- and dose-dependent growth inhibition and apoptosis involving Akt pathway inactivation in U251 glioblastoma cells

Antitumor effects of ginkgolic acid in human cancer cell occur via cell cycle arrest and decrease the Bcl-2/Bax ratio to induce apoptosis.

Inhibition of glioblastoma growth and angiogenesis by gambogic acid: an in vitro and in vivo study.

Gambogic acid impairs the maintenance and therapeutic resistance of glioma stem cells by targeting B-cell-specific Moloney leukemia virus insert site 1

Chlorogenic Acid Inhibits Human Glioma U373 Cell Progression via Regulating the SRC/MAPKs Signal Pathway: Based on Network Pharmacology Analysis

Effect of Gambogic Acid on Growth Activity and Invasion in Renal Carcinoma 786-O Cells

TGX-221 Inhibits Proliferation and Induces Apoptosis in Human Glioblastoma Cells

The Natural Flavonoid Galangin Elicits Apoptosis, Pyroptosis, and Autophagy in Glioblastoma.

Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells.

Anticancer Effect and Apoptosis Induction of Gambogic Acid in Human Leukemia Cell Line K562 In Vitro

Nitidine Chloride Inhibits the Malignant Behavior of Human Glioblastoma Cells by Targeting the PI3K/AKT/mTOR Signaling Pathway

Ginkgolic acid inhibits the growth of renal cell carcinoma cells via inactivation of the EGFR signaling pathway

Cyclovirobuxine D Inhibits Cell Proliferation and Migration and Induces Apoptosis in Human Glioblastoma Multiforme and Low-Grade Glioma

Anti-Invasive Effect Of Gambogic Acid In Mda-Mb-231 Human Breast Carcinoma Cells

20(S)-Ginsenoside Rg<sub>3</sub> Inhibits Human Glioma Cell Growth through the Suppression of Voltage-Gated K<sup>+</sup> Channels

20(S)-Ginsenoside Rg3 Inhibits Human Glioma Cell Growth through the Suppression of Voltage-Gated K+ Channels